© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Mavacamten stands as a small molecule medication targeted toward cardiac health, recognized in both clinical research and pharmaceutical supply as a specialized option for patients facing hypertrophic cardiomyopathy. Chemically, it holds the molecular formula C19H19N3O5 and reveals a molecular weight of 369.4 g/mol, offering a clear reference point for those in research or manufacturing. The physical form typically reflects a white to off-white solid, sometimes appearing as a fine powder, occasionally manifesting as crystalline flakes. This solid showcases low solubility in water but demonstrates a better profile with organic solvents, which chemists find advantageous when planning extractions, purifications, or compounding processes. The IUPAC name gives clarity for regulatory documents, or when cross-referencing chemical abstracts and supply databases: (3-(2-(4-(6-Aminopyridin-3-yl)phenoxy)ethyl)benzamido)oxyacetic acid. Those sourcing or handling the compound can look to its HS Code, often aligned with pharmaceutical raw materials or specialty chemicals — commonly listed as 2934.99, aligning with heterocyclic compounds containing an unfused pyridine ring.
The structure of Mavacamten features a benzamido core, functionalized with divalent ether and amino side groups, which influence both electronic distribution and intermolecular interactions. Its architecture sets the stage for selective binding that supports its function as a myosin inhibitor, interrupting adenosine triphosphate hydrolysis within cardiac sarcomeres. Beyond pharmacology, the structure affects reactivity in the lab—stability in air, resistance to hydrolysis under mild conditions, and moderate melting range, which sits between 130°C and 140°C. Handling in bulk necessitates tight environmental controls, given that the product can degrade under elevated temperatures or persistent light exposure. Its powder form can transition to a more pearl-like or glassy solid if recrystallized slowly, useful information for anyone dealing with its formulation or packaging. Researchers need to know mass density, which hovers close to 1.3 g/cm³, since calculations on scaling up, storage, or solution preparation often turn on such specifics.
Mavacamten usually arrives as a nearly odorless powder, lacking prominent taste, easy to distinguish from other fine pharmaceutical solids because of its tendency toward cohesive clumping in high humidity. Under the microscope, the powder shows fine grains with some transparent or faintly pearlescent particles. Direct exposure of a fresh batch often brings a soft sheen, especially under halogen lamp inspection. Its low solubility in cold water and a higher affinity for polar organic solvents like DMSO, methanol, or ethanol influences laboratory choices: suspension for animal studies, or solution for in vitro assays, shifts depending on the ultimate purpose. Achieving full dissolution at higher concentrations may require gentle heating and persistent agitation in a controlled environment.
Safety analysis reveals that Mavacamten does not fit classic industrial hazard profiles, but laboratory staff need protection from fine particulates, which can become airborne during weighing or transfer. Data sheets consistently advise dust masks and gloves, not solely from acute toxicity but as a precaution against inhalation and skin sensitization over repeated contact. The oral LD50 in rodents points to low acute toxicity, but, as with many research-only compounds, chronic data remain limited, urging a precautionary approach over extended exposures. Combine material safety practices with appropriate containment, and the likelihood of harm stays extremely low—still, tracking spills and preventing accidental contamination must remain a daily habit for technicians and researchers. Shipping classifies it as non-hazardous under most regulatory labels, but it does count as a potentially harmful chemical since its biochemical action targets cardiac function, and improper use outside approved research environments risks health complications. Sources for raw Mavacamten usually link back to high-purity chemical intermediates—specialty manufacturers synthesize it through multi-step routes involving pyridine derivatization and selective amide bond formations, often requiring dense analytical verification using NMR, IR, MS, and HPLC to ensure trace impurities stay below the stringent pharmacopeia thresholds.
People working in research, compounding, or pharma logistics understand that knowing the complete physical and chemical profile keeps projects on track and costs down. I have seen quality assurance hiccups crop up simply because a key property—say, hygroscopicity or thermal stability—was ignored, which set off a cascade of rework, returned supply, and delayed results. When customers ask about "flakes", "powder", or "solution", expectations become sharper. Understand the density, and storage space calculation gets easier; miss this detail, and facility design runs into snags. In my own work, recognizing how a compound tolerates moisture—whether it cakes or flows freely—makes a world of difference when blending or measuring on the bench. Those nuances, like the faint sheen under a light or that tendency to clump in summer air, aren't just trivia, they turn routine handling into quality output or wasted effort. Knowing the actual specifications sets the bar for batch-to-batch reproducibility, a topic that haunts anyone who’s wrestled with cross-lab validation or scale-up headaches. Documentation isn’t bureaucracy, it’s how projects survive regulatory audits and fend off expensive surprises.
Direct experience taught me that upfront attention to the details—a proper specification sheet covering appearance, solubility, density, safe handling—pays off in smooth operations. For storage, airtight high-density polyethylene or amber glass bottles control moisture and protect against light degradation. Implementing written protocols for weighing reduces inhalation risk and ensures nobody "eyeballs" delicate repairs to purity or quantity. Chemistry teams that set up—literally label—dedicated workspaces for pharmaceutical solids sidestep cross-contamination or unexpected reactivity with neighboring reagents. Quality departments should record actual property measurements for every incoming batch, not just relying on a supplier’s word. Engaging with suppliers who publish in-depth data on everything from crystal habit to HS Code makes regulatory paperwork smoother, and traceability more robust. Companies can standardize checks on all these fronts, yet—more crucial than systems—is building a team that knows why to bother: all it takes is one missed detail and a lab can face a costly recall or audit setback. Investment in practical training, better storage, and transparent raw material sourcing translates to safer workspaces and more reliable science, the anchor for any pharmaceutical R&D effort.
